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Vigabatrin use in some epilepsy patients has been associated with persistent visual field constriction and retinal dysfunction.
The mechanism is unknown, but could be related to vigabatrin, chronic epilepsy, GABA toxicity, or the effect of a metabolite
in combination with a predisposing genotype. The aim of this study was to investigate the latter two hypotheses. Levels of
brain gamma-aminobutyric acid (GABA) measured by nuclear magnetic resonance spectroscopy were similar in subjects taking
vigabatrin who developed visual field constriction and those who did not. We tested whether allelic heterogeneity of the ornithine
aminotransferase gene occurs in the affected patients. No clinically significant mutation was detected, although a common
intronic polymorphism was identified.
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INTRODUCTION
Vigabatrin is a relatively selective, irreversible in-
hibitor of GABA-transaminase, resulting in increased
amounts of brain gamma- aminobutyric acid (GABA)
and ornithine1. Vigabatrin is used in over 60 coun-
tries in the treatment of partial epilepsy and infan-
tile spasms. Persistent, sometimes severe visual field
constriction was considered a rare (< 1 :1000) occur-
rence, until reports in 1997–1999 found visual field
constriction in as much as 40% of subjects on viga-
batrin monotherapy2–4. Follow-up of these patients 3–
6 months after stopping the drug has shown largely
no improvement in the visual field defect5. The cause
of the visual field constriction is unknown. Ocular
electrophysiologic studies have shown abnormal reti-
nal responses, the likely site of damage6–9. Several
mechanisms have been postulated, including toxic-
ity of GABA, a consequence of epilepsy, antiepilep-
tic drug side effect, vigabatrin alone or in combina-
tion with other antiepileptic drugs, and finally, ge-
netic variation in the mitochondrial enzyme ornithine
δ-aminotransferase (OAT)10, 11. In the autosomal re-
cessive condition, gyrate atrophy of the choroid and
retina mutations in the OAT gene cause progressive
peripheral and central visual field loss beginning in
the second decade12, 13. We report here results of
proton magnetic resonance spectroscopic measure-
ments of GABA in 17 adult patients (aged 25–71
years, eight men, nine women), taking vigabatrin
for refractory complex partial epilepsy, and molecu-
lar analysis of the OAT gene in three subjects with
vigabatrin-associated visual field defect determined by
Goldmann perimetry.
MATERIALS AND METHODS
Genomic DNA was extracted from venous blood sam-
ples obtained under an ethically approved protocol.
Individual exons of the OAT gene were amplified by
PCR using previously published primer sets14. In ad-
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dition, the following primers were used to amplify
Exons 7 and 11: 7F: 5′ TAT GCT TTC AGA TTT
CCA AGT G 3′; 7R: 5′ CAT CAC AAA CAG CTA
ACT CGA C 3′; 11AF: 5′ CAT ACA TAT GGC
AAG GGA TGT 3′; 11AR: 5′ TAG AGG ACT TGA
TTT AGA GGC 3′; 11BF: 5′ AGA ACA ACG TTT
ATG AAC CTG 3′; 11BR: 5′ TCA TCA CAA AAC
AGA CAT TTG 3′. The reaction mixture (50 µL)
contained 100 ng genomic DNA, 10 mmol Tris-HCl
(pH 8.3), 60 mmol KCl, 100 ng specific primers,
MgCl2 of 1.5 mmol (Exons 7, 11), 2.0 mmol (Exons
3, 4, 8, 9), 3 mmol (Exons 5, 10), 4 mmol (Exon 6),
and 200 µmol dNTPs, 2.5 U Taq DNA Polymerase
(Perkin-Elmer). PCR products were electrophoresed
on 1% agarose gels and visualized with ethidium bro-
mide. After purification using QiaQuick columns (Qi-
agen), PCR products were sequenced on an Applied
Biosystems automated DNA sequencer model 373A.
Mutations were confirmed by sequencing both strands,
and amplification followed by sequencing of a second
PCR product.
Proton magnetic resonance spectroscopy was per-
formed at 2.1 Tesla (89.43 MHz for 1H) with an 8 cm
distributed capacitance 1H transceiver radio-frequency
coil. From the scout image, a 3.0 × 1.5 × 3.0 cm
(14 cm3) volume in the occipital cortex was chosen for
spectroscopic measurements. Homonuclear editing of
the 3.0 ppm C4 GABA resonance was performed us-
ing the spin–spin (J ) editing pulse sequence described
previously15. The localization techniques were 3D-
ISIS sequence, outer volume suppression, plane selec-
tive excitation, and a surface spoiler coil. An inversion
recovery pulse and a semiselective refocusing pulse
were used for water suppression. Spectral editing was
used to separate the GABA C4 resonance at 3.0 ppm
from overlapping resonances by applying a 26.5 ms
DANTE pulse applied symmetrically in time about the
center of the sequence to improve editing selectivity to
the 1.9 ppm C3 resonance. Spectral acquisition condi-
tions were TR 4.1 s, TE 68 ms, sweep width 15000 Hz,
and acquisition time 546 ms.
RESULTS
Direct DNA sequencing of the entire coding re-
gion of the OAT gene in three subjects with
vigabatrin-associated visual field defect detected no
functional mutations. The only sequence variant
IVS6+ 14 G → A, found in one of the three af-
fected subjects, has been previously reported as a com-
mon polymorphism with a worldwide distribution14.
Median-edited GABA (GABA plus homocarnosine)
was the same in affected (2.5 mM, number 3, range
2.3–3.5) and unaffected (2.4 mM, number 14, range
2.0–2.9, interquartile 2.3–2.8) patients. The vigabatrin
doses were similar for the affected (median 5 g per
day, number 3, range 4.5–6) and unaffected (median 4,
number 14, range 2–6, interquartile 3.1–4.5) patients.
DISCUSSION
The mechanism of vigabatrin-associated visual field
defect is unknown. The relationship between dose or
duration of therapy with vigabatrin and the risk of de-
veloping visual constriction is controversial. Although
vigabatrin weakly binds to a variety of transaminases,
its direct effect on OAT is thought to be minimal. The
increase in ornithine is attributed to the increase in
GABA inhibiting OAT1. Roubertie11 proposed a par-
tial defect in OAT made complete by vigabatrin as
the mechanism for retinal toxicity because of simi-
larities between the vigabatrin-associated visual field
defect and gyrate atrophy of the choroid and retina.
Although, theoretically, subjects that are heterozygous
carriers or have an otherwise benign polymorphism
in the OAT gene could be at higher risk of an ad-
verse drug effect, the absence of mutations in three
affected subjects suggests that it is not required for
the vigabatrin-associated field defect to occur. In ad-
dition, Krauss et al.11 have reported normal serum or-
nithine levels in two vigabatrin-treated subjects with
visual field loss.
Another proposed mechanism is direct retinal toxic-
ity by above normal GABA concentrations. If GABA
were the toxic agent, then GABA levels might pre-
dict the risk of developing the visual abnormality. We
found that brain GABA levels were not significantly
higher in vigabatrin-treated patients who experienced
visual field constriction, compared with those who did
not. Another point against the GABA hypothesis is
that there are several other antiepileptic drugs, such
as gabapentin, lamotrigine, tiagabine, topiramate, that
increase GABA in the human visual cortex15–17, but
similar retinal complications have not been reported
with their use5.
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